Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These
populations have an underlying predisposition to deficient insulin secretion, which has a key …
populations have an underlying predisposition to deficient insulin secretion, which has a key …
Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases
KF Tsai, YL Chen, TTY Chiou, TH Chu, LC Li, HY Ng… - Antioxidants, 2021 - mdpi.com
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering
agents. Apart from their glucose-lowering effects, large clinical trials assessing certain …
agents. Apart from their glucose-lowering effects, large clinical trials assessing certain …
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020Table. No title available.
R Chawla, SV Madhu, BM Makkar… - Indian journal of …, 2020 - journals.lww.com
Guidelines RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2
Diabetes Mellitus 2020Table. No title available.
Diabetes Mellitus 2020Table. No title available.
Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review
Abstract Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a relatively newer class of
anti-hyperglycemic medications that reduce blood glucose by inhibition of renal glucose re …
anti-hyperglycemic medications that reduce blood glucose by inhibition of renal glucose re …
Expert opinion: optimum clinical approach to combination-use of SGLT2i+ DPP4i in the Indian diabetes setting
M Chadha, AK Das, P Deb, KK Gangopadhyay… - Diabetes Therapy, 2022 - Springer
Abstract The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized
for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio …
for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio …
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
Y Yan, B Liu, J Du, J Wang, X Jing, Y Liu… - ESC heart …, 2021 - Wiley Online Library
Aims This study aimed to determine the effects of sodium‐glucose cotransporter‐2 inhibitor
(SGLT2i) in heart failure with reduced ejection fraction (HFrEF), compare the effect of …
(SGLT2i) in heart failure with reduced ejection fraction (HFrEF), compare the effect of …
Glucose measurement in body fluids: a ready reckoner for clinicians
Background and aims Blood glucose measurement is central to the diagnosis and
management of patients with diabetes. Considering that a clinician relies heavily on blood …
management of patients with diabetes. Considering that a clinician relies heavily on blood …
Fixed-dose combination of dapagliflozin+ sitagliptin+ metformin in patients with type 2 diabetes poorly controlled with metformin: phase 3, randomized comparison …
RK Sahay, R Giri, JV Shembalkar, SK Gupta… - Advances in …, 2023 - Springer
Introduction This study compared efficacy and safety of triple drug fixed-dose combination
(FDC) of dapagliflozin (DAPA)+ sitagliptin (SITA)+ metformin (MET) extended release (ER) …
(FDC) of dapagliflozin (DAPA)+ sitagliptin (SITA)+ metformin (MET) extended release (ER) …
Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus—A Real-Life Clinical Practice Study
In this paper, we aim to evaluate the efficacy of antidiabetic cardioprotective molecules such
as Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 …
as Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 …
Effects of dapagliflozin on cardiovascular events, death, and safety outcomes in patients with heart failure: a meta-analysis
XD Zheng, Q Qu, XY Jiang, ZY Wang, C Tang… - American Journal of …, 2021 - Springer
Background Several clinical trials of dapagliflozin in patients with type 2 diabetes mellitus
(T2DM) at elevated cardiovascular risk have observed reduced hospitalization for heart …
(T2DM) at elevated cardiovascular risk have observed reduced hospitalization for heart …